Stocktoria
CRISPR Therapeutics AG CRSP
CRISPR Therapeutics AG financials (annual)
Bars are annual figures from 2016 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $3.5M | $37.3M | $371.2M | $1.2M | $915.0M | $719,000 | $289.6M | $3.1M | $41.0M | $5.2M |
| R&D expense | $284.8M | $310.2M | $387.3M | $461.6M | $340.6M | $221.4M | $179.4M | $113.8M | $69.8M | $42.2M |
| Operating income | -$664.6M | -$466.6M | -$222.5M | -$673.2M | $373.5M | -$354.4M | $46.7M | -$158.9M | -$64.6M | -$68.1M |
| Income tax | $3.6M | $3.6M | $2.9M | -$325,000 | $1.9M | $809,000 | $448,000 | $553,000 | $1.7M | $484,000 |
| Net income | -$581.6M | -$366.3M | -$153.6M | -$650.2M | $377.7M | -$348.9M | $66.9M | -$165.0M | -$68.4M | -$23.2M |
| EPS (diluted) | $-6.47 | $-4.34 | $-1.94 | $-8.36 | $4.70 | $-5.29 | $1.17 | $-3.44 | $-1.71 | — |
| Operating cash flow | -$345.0M | -$142.8M | -$260.4M | -$495.7M | $539.0M | -$238.4M | $56.7M | -$96.2M | -$70.1M | -$55.3M |
| Free cash flow | -$345.9M | -$144.7M | -$269.8M | -$532.9M | $457.3M | -$256.7M | $50.0M | -$99.0M | -$77.9M | -$58.3M |
| Cash & equivalents | $347.6M | $298.3M | $389.5M | $211.9M | $923.0M | $1.2B | $943.8M | $456.6M | $239.8M | $315.5M |
| Total assets | $2.3B | $2.2B | $2.2B | $2.2B | $2.8B | $1.8B | $1.1B | $489.0M | $271.3M | $345.0M |
| Total liabilities | $343.4M | $310.0M | $346.8M | $367.6M | $352.4M | $163.7M | $127.3M | $96.8M | $83.5M | $112.1M |
| Shareholders' equity | $1.9B | $1.9B | $1.9B | $1.9B | $2.4B | $1.7B | $939.4M | $392.2M | $187.8M | $232.8M |
Growth · year-over-year · Revenue CAGR -4.2%
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue growth | -90.6% | -89.9% | +30885.5% | -99.9% | +127154.9% | -99.8% | +9169.8% | -92.4% | +693.9% | +1990.7% |
| Net income growth | — | — | — | -272.2% | — | -621.8% | — | — | — | — |
| EPS growth | — | — | — | -277.9% | — | -552.1% | — | — | — | — |
| Free cash flow growth | — | — | — | -216.5% | — | -613.5% | — | — | — | -200.1% |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.